Testing a new IVIG for people with primary immune deficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 65 years old.
- You have a confirmed diagnosis of primary immunodeficiency (like CVID or XLA) with low IgG levels.
- You either have never had IVIG before, or you've been on IVIG every 3 or 4 weeks for at least 6 months.
- Your blood counts and liver/kidney tests are within acceptable ranges.
- You are not pregnant or planning pregnancy, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This trial tests an investigational intravenous immunoglobulin (IVIG) called Boya for people with primary immune deficiencies like CVID or XLA. It aims to see if the treatment is safe and works well to prevent infections.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.